{"ticker": {"uuid": "426e8250-cfc3-46db-b7ab-2f8a9bc74c89", "symbol": "ORMP", "name": "Oramed Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback", "summary": "Oramed Pharmaceuticals (ORMP) stock is reflecting a strategic pivot following the discontinuation of its oral insulin program for type 2 diabetes due to insufficient efficacy. The company, a small-cap clinical-stage biotech, is now focusing its oral drug delivery technology on ot", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/oramed-stock-trades-quietly-as-diabetes-pill-strategy-pivots-after-fda/69789385", "source_name": "Ad Hoc News", "published_at": "2026-07-17T17:40:58", "published_display": "17 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of Oramed Pharmaceuticals Inc. \u2013 NASDAQ:ORMP", "summary": "This article provides financial information for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), specifically focusing on its forward price-to-sales ratio. It appears to be a financial data snippet from a platform like TradingView, listing company details and market data. The content ", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T13:43:24", "published_display": "09 Jul 2026 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Oramed Pharmaceuticals Inc. \u2013 NASDAQ:ORMP", "summary": "This article provides general financial information for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), focusing specifically on its enterprise value to EBIT forward. It indicates that such financial data is available through TradingView, which sources its information from ICE Data S", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T00:12:02", "published_display": "09 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospects", "summary": "Oramed Pharmaceuticals is drawing investor attention due to its oral drug delivery platform, which aims to develop capsule-based alternatives to injectable biologic drugs. The Nasdaq-listed biotech focuses on clinical-stage development, with a notable project being an oral insuli", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/oramed-pharmaceuticals-highlights-oral-drug-platform-as-investors-assess/69726099", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T18:34:19", "published_display": "08 Jul 2026 18:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifeward Enters Securities Purchase Agreement Under Oramed Financing Framework", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/lifeward-enters-securities-purchase-agreement-212258744.html", "source_name": "MT Newswires", "published_at": "2026-07-07T21:22:58+00:00", "published_display": "07 Jul 2026 21:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals outlines its oral drug strategy as Nasdaq-listed biotech pursues long-term gr", "summary": "Oramed Pharmaceuticals, a Nasdaq-listed biotechnology company, is focused on developing oral formulations of injectable drugs for metabolic and liver diseases. The company aims to improve patient convenience and adherence by leveraging proprietary oral delivery platforms that pro", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/oramed-pharmaceuticals-outlines-its-oral-drug-strategy-as-nasdaq-listed/69715057", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:41:34", "published_display": "07 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Oramed Pharmaceuticals Inc. \u2013 NASDAQ:ORMP", "summary": "This article focuses on the \"Price to earnings forward\" metric for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), as presented on TradingView. It provides a brief financial overview for the company, indicating key data points and the source of the market and reference data.", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T04:10:23", "published_display": "06 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Oramed Pharmaceuticals Inc. \u2013 NASDAQ:ORMP", "summary": "This article focuses on the \"Price to book forward\" metric for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP). It provides a high-level overview of the company's financial data available on TradingView, listing the market and stock information. The content primarily acts as a placeho", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T18:09:21", "published_display": "04 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Oramed Pharmaceuticals Inc. \u2013 NASDAQ:ORMP", "summary": "The article provides a financial metric, \"Enterprise value to revenue forward,\" for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP). It appears to be a stub or a section of a larger financial data page, showing the company's ticker, exchange, and market status. The content itself does", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T10:40:36", "published_display": "04 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Avraham Gabay Sells 73,360 Shares of Oramed Pharma", "summary": "Avraham Gabay, CFO of Oramed Pharmaceuticals Inc's subsidiary, sold 73,360 shares of ORMP on July 1, 2026, reducing his holdings to 671,785 shares. This sale aligns with a trend where Gabay has sold shares but made no purchases over the past year, while the company has seen two i", "url": "https://www.gurufocus.com/news/8943750/insider-sell-avraham-gabay-sells-73360-shares-of-oramed-pharmaceuticals-inc-ormp", "source_name": "GuruFocus", "published_at": "2026-07-03T00:41:05", "published_display": "03 Jul 2026 00:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals COO & Cbo Sold Shares Worth Over $611K", "summary": "Oramed Pharmaceuticals' COO & CBO, Hexter Joshua, sold 137,000 shares of common stock worth $611,431 on July 1, 2026. The transaction was conducted under a Rule 10b5-1 plan adopted on March 30, 2026, with shares sold at a weighted average price of $4.463. Following this sale, Hex", "url": "https://www.tradingview.com/news/tradingview:23ca4ee733ca8:0-oramed-pharmaceuticals-coo-cbo-sold-shares-worth-over-611k/", "source_name": "TradingView", "published_at": "2026-07-02T20:41:06", "published_display": "02 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (NASDAQ: ORMP) COO sells 137K shares after option exercise", "summary": "Oramed Pharmaceuticals' COO and CBO, Joshua Hexter, exercised 50,000 stock options at $3.69 per share and subsequently sold 137,000 common shares at a weighted average price of $4.463 per share. These transactions, which occurred on July 1st and 2nd, 2026, were conducted under a ", "url": "https://www.stocktitan.net/sec-filings/ORMP/form-4-oramed-pharmaceuticals-inc-insider-trading-activity-08cbc29dc66d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:41:06", "published_display": "02 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORAMED (NASDAQ: ORMP) CFO executes pre-planned sale of 73,360 shares", "summary": "Oramed Pharmaceuticals Inc.'s Chief Financial Officer, Avraham Gabay, sold 73,360 shares of common stock on July 1, 2026, at a weighted average price of $4.5085 per share. This transaction was part of a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. Following th", "url": "https://www.stocktitan.net/sec-filings/ORMP/form-4-oramed-pharmaceuticals-inc-insider-trading-activity-32c6febd7051.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:41:05", "published_display": "02 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Incorporated Financial Disclosures & SEC Filings", "summary": "This article provides access to Oramed Pharmaceuticals Inc.'s SEC filings and other financial documents. It lists earnings reports, quarterly (10-Q), and annual (10-K) reports from Q1 FY2021 through Q1 FY2026, highlighting key financial outcomes like net income and strategic deve", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/documents/", "source_name": "TradingView", "published_at": "2026-07-02T07:41:06", "published_display": "02 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ORAMED PHARMACEUTICALS INC. For: 1 July By Investing.com", "summary": "This article from Investing.com reports on Form 144 filings for ORAMED PHARMACEUTICALS INC. for July 1st. It emphasizes that trading in financial instruments and cryptocurrencies carries significant risks and advises investors to be fully informed before making investment decisio", "url": "https://m.za.investing.com/news/stock-market-news/form-144-oramed-pharmaceuticals-inc-for-1-july-93CH-4352375?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T16:39:17", "published_display": "01 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (NASDAQ: ORMP) Form 144 notes 93,360 RSU shares on 06/18/2026", "summary": "Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) filed a Form 144 revealing 93,360 shares of Common Stock linked to the vesting of Restricted Stock Units (RSUs) on June 18, 2026. The filing indicates the shares were issued without consideration, with Nasdaq listed as the market and an ", "url": "https://www.stocktitan.net/sec-filings/ORMP/144-oramed-pharmaceuticals-inc-sec-filing-d91af988e116.html", "source_name": "Stock Titan", "published_at": "2026-07-01T15:48:05", "published_display": "01 Jul 2026 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "137,000 shares flagged for sale by Oramed (NASDAQ: ORMP) in Form 144", "summary": "Oramed Pharmaceuticals has filed a Form 144, indicating proposed sales of 137,000 common shares with an associated value of $658,970.00. The filing also notes 108,000 shares issued from RSU vesting in 2023 and 50,000 shares acquired from employee stock option exercises on July 1,", "url": "https://www.stocktitan.net/sec-filings/ORMP/144-oramed-pharmaceuticals-inc-sec-filing-3d5184b6b74a.html", "source_name": "Stock Titan", "published_at": "2026-07-01T15:39:17", "published_display": "01 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (NASDAQ: ORMP) revises bylaws and restructures Scilex note obligations", "summary": "Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) has updated its corporate bylaws, refining procedures for stockholder action by written consent. Concurrently, Oramed has renegotiated and extended the payment schedule for approximately $36.2 million in debt owed by Scilex Holding Compa", "url": "https://www.stocktitan.net/sec-filings/ORMP/8-k-oramed-pharmaceuticals-inc-reports-material-event-8d02b5b7c2d2.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:09:35", "published_display": "30 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BML Investment Holds 2.5% of Oramed (ORMP) in Amended 13G/A", "summary": "BML Investment Partners, L.P. has filed an amended Schedule 13G/A, reporting a beneficial ownership of 1,026,269 shares, or 2.5% of Oramed Pharmaceuticals Inc. (ORMP). Braden M. Leonard is identified as the indirect owner through BML Capital Management, LLC. The filing specifies ", "url": "https://www.stocktitan.net/sec-filings/ORMP/schedule-13g-a-oramed-pharmaceuticals-inc-amended-passive-investment--bf75d0084773.html", "source_name": "Stock Titan", "published_at": "2026-06-29T14:34:39", "published_display": "29 Jun 2026 14:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOTmF4N3I4SlM0NGdnaUk4N1ZIYW9TRUNrYlNFYzNzSTlsd2hoVkhwc0ZuQWNCV3Vzdjl6Q2FxdzBaVFlQa1R2SklKWEo2UWRlZ1lfZjR3TnZEdDlmM3otWTNVLXByTFl5RDVfNzdvWnRrSFdZSElBbjBVZWpuUVFpMzN1LXVNbGJBdnJqNUQ0TXk2MDcyT0xpa0ljWjFUblV1UHhONl83UEk2RmV4bWwwS0JzOHVDQzNZbGkwTkI1Mzl5Wk5zYTdpeXdlR2k?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Incorporated Actuals & Estimates (MUN:OJU1)", "summary": "This article provides financial actuals and estimates for Oramed Pharmaceuticals Incorporated (MUN:OJU1), including income statement, balance sheet, and cash flow data. It also covers analyst price forecasts, historical stock performance, upcoming earnings dates, and key financia", "url": "https://www.tradingview.com/symbols/MUN-OJU1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:20", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Incorporated Actuals & Estimates (DUS:OJU1)", "summary": "This article provides financial actuals and analyst estimates for Oramed Pharmaceuticals Incorporated (DUS:OJU1), including income statement, balance sheet, cash flow, and valuation metrics. It offers a stock forecast with max and min estimates, historical price data, and details", "url": "https://www.tradingview.com/symbols/DUS-OJU1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:54", "published_display": "26 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet \u2013 Company Announcement - FT.com", "summary": "Oramed Pharmaceuticals Inc. issued a letter to shareholders detailing significant developments, including its inclusion in the Russell 2000 and 3000 indexes, substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in cash and asset", "url": "https://markets.ft.com/data/announce/detail?dockey=600-202606251135PR_NEWS_USPRX____LN92360-1", "source_name": "Financial Times", "published_at": "2026-06-25T16:35:00", "published_display": "25 Jun 2026 16:35", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:ORMP)", "summary": "This article provides an overview of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), detailing its stock performance, financial actuals and estimates, and analyst forecasts. As of the article's publication time, ORMP's stock price was $5.00, having increased significantly over the pa", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T15:40:10", "published_display": "25 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed\u2019s portfolio swells: Alpha Tau stake up $128M, Scilex loan repaid", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQbXJSSnI4UXYzVXYwNW44SFlScTBHVXZ0RC04UjBJVmd4MlJGUk9hYVQybUlOakR6bmlWbl9CbENVTVRJVTViZnRvanhzWHVZTDd6TEtVTHZteDJTa29HQmw5SjBYcmtrcE9qVmUyS24xRFlSa202WEVpekNRaGlzVnZQU3NHdG9SZXVtNU81WGlELTdsWlY5aVVDb0hJMVVWRHR4LTVaU2xuXzg0RGJVZ0c2a1dmUG85eW5Z?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORMP SEC Filings - Oramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Oramed Pharmaceuticals Inc. (ORMP) SEC filings, including 10-K, 10-Q, and 8-K reports. It details recent material events and financial information, such as an $18 million payment from Scilex Holdings Inc. and a declared cash dividen", "url": "https://www.stocktitan.net/sec-filings/ORMP/page-3.html", "source_name": "Stock Titan", "published_at": "2026-06-21T17:41:08", "published_display": "21 Jun 2026 17:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals to Join Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is scheduled to join the U.S. small cap Russell 2000\u00ae and broad-market Russell 3000\u00ae Indexes. This inclusion will become effective after the close of US markets on Friday, June 26, 2026, and for trading at the market open on Monday, June", "url": "https://www.morningstar.com/news/pr-newswire/20260617io85985/oramed-pharmaceuticals-to-join-russell-2000-and-russell-3000-indexes", "source_name": "Morningstar", "published_at": "2026-06-19T01:40:10", "published_display": "19 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Oramed Pharmaceuticals Inc (ORMP), noting its current valuation score of 8.94 and its ranking within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 1.45, contrasting it with recent high", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ormp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:55", "published_display": "18 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Oramed Pharmaceuticals Inc (ORMP), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis suggests a \"Sell\" signal based on moving averages and indicator", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ormp/technical", "source_name": "TradingKey", "published_at": "2026-06-18T07:38:57", "published_display": "18 Jun 2026 07:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Oramed Pharmaceuticals Inc (ORMP) currently lacks an earnings forecast score, with the Biotechnology & Medical Research industry average being 8.13. Analyst forecasts set the price target at $3.25, with no deviation between high and low estimates. The company has not yet disclose", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ormp/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:38:57", "published_display": "18 Jun 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Oramed Pharmaceuticals Inc (ORMP), identifying major individual and institutional holders. It provides a breakdown of shareholder types and tracks institutional shareholding changes over several quarters, along with significant sh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ormp/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T14:10:19", "published_display": "17 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (ORMP) Set to Join Russell 2000 and 3000 Indexes in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQalBhNEh1TDlGS05ndkNLMEdqMXlKcHN1NENRNWhZTDlnZ2NaQzFQMXR2dVAzeEg3UUhock03aS0zRmE2RndjdXgybURQVDBMS1NBZTdTZ0NuQURfZHdRaDlUZzVvLWhQZ2Q3UDhwa3dzRzdhWl9nWi1BV0o3elFVZm8wVzhHZnMxVVk0c0lRSG5HaHF2UThKQk1Kb0xaTHl3VFFtSlFlYlZvTE9NM3VkeE9SQzNxcmFucXhhWk1XWk1HbEhmRk54R25wOS1vX2Qxd0M2WnkwYw?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals (ORMP) Faces Selling Pressure; Key Levels in Focus - Risk Reward Setups", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOdXAtVVZWOVZxLXNkYlk1RllZZzBjZWZRQUtLU1lCRy1LS181ei1JOGZHVVdIM09Nc0F0ZkN5OGlWZ0JVQjd3MlV4VWtvYjQ0TEpqb0FrZEp2SnRhV21udks3Y19XbkF5SlU0dmtkZGdPX0FySDZoLWJhZ2taclQ4SlhLR0xPZWtmR2Q3SHl6TElNQ1N1Ui1BVHpxcnNhZW83LTlmQ1BDVWd1TFRKM3Q3aUJRbnY?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals (ORMP) Holds Near Key Support Amid Modest Decline - Percent Below MA", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPZ0xPclBBQjV3TV8tT0pCZlFWakFMQWhrX2ZLeWVJYzVIWTd4Z2haU2h6d0d3M3dKRjZfZXR5M1NfYmxiRDNQaldXZEpvczc1RVZjT0tMdm9mSjQ3cndlYXVMVHY5Q1dhODAyZGt4TnkwZUlxaTZvUFFXanE0MGdUdk15SGJvbEJfVGZzc2p5cHQyOWJrUFpPMmhRVm9saTA4UGZUcE95MjFxUnYzRUZoZV9lcl9WUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxONmpPQmZvbGJpM1R4MTR6WHhUVVV0eHFLZjhkaW5oamlpWS1kZWZ1OFVjcTdiaW5iS0EtbTdhMHg2OU9jSlE1UUNOZXVuWFpmSWlRNW1kUEhFdlA0c1FZMDZXNy1Ec1J3bDFoLURQV3lUOHNjVng0RjNQZ3RsOURnRlprRGd4bTRhdXlZSHJDUDl4UzJhZzlXbnA0eXBmWGhiYkxabUFFUlVJaG50M2RmeGhMXzJRbG15NDNPYS1rUm5GQ0c2T0l6VllvOEdLMWc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oramed-q1-earnings-snapshot-213617884.html", "source_name": "Associated Press", "published_at": "2026-05-19T21:36:17+00:00", "published_display": "19 May 2026 21:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks", "summary": "", "url": "https://finance.yahoo.com/news/spotlight-oramed-pharmaceuticals-two-other-120523659.html", "source_name": "Simply Wall St.", "published_at": "2026-05-13T12:05:23+00:00", "published_display": "13 May 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNYWVuQ19uenhfR01hUzJmcUp1YjVkektPcDBPNEV6UzlLdXZ3WDlleWFCQWtLYUE0T1ZOQjhMSWc4bGRjTlF1Xzh1NFlQWDlWSVBCNG9sVy1OUVdPQVZBZUU3eXJneXhsY0xjY2hQRUVLZ2EtZ1ptXzZTTC0yZWtZZWJmSlNZQm9zWHVKdDNsTmtZN3RzR0JMTURnMW5rbV9LZ1RIZ251RkppV2c?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Top 10 healthcare stocks with highest dividend yield amid volatile markets (ORMP:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQaU40M2dnNk1rd3Nna1dqVGhmX0ZscDJHUkR2TjF6dWxZaGZoV3FYMWVCdXU0T3NHVlJFanlic2t3VG5wRDBBZ2lnSXpBWWJXSmRYMTlJcFlqcU1WVFptbHR5VEh3cDRJT095UURnUGptdmZTOV92MDQydEN5ZUVxYndIMEdRakdqOVRPOXV4WjhwOGlnSlVPdjVpV0ZVQTRSakpyMEdPcTFIbm5iaXROdTln?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed and Lifeward Announce Strategic Transaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOczBySEF1Vy1BNUR4d2x2ejFfa1YtMnd3djB4bEJ1V2IwWkczZy01a19ybkpUT1FkYndqa3JQTTNLcURXc0lYUXl0aHNGYnQzR1l1WVM5dzFiSXBSTmxEbDZSTi1MU3kzX2pwRmdMdm1BaEduSEpvZ3RkRUthLWhhaGxndnJkd2lJU1lGeERIX2dvYlp3bW94Y1c3UUlhLXExYlV1Q3NUZnVGQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxPc3NEdVhOTFlFQ0NyS2E4aHR3UGNiVjBCMjZpZTNUSm5VQnNWSDgyTlFDZTRoNzh5aWdlZkdGczc3TzZhbE5tQlpYWGpablZvZHpYVUg1WVBueFpsMGs5Ql81T01ScFBYWVF0ZUpoNHRYR0hvVERSMFNBejcwQ1ZUcVlSWG5RZ0JFRUY2aGpENTFlOUEwb1VPVHU3NXI3Z2hFLVBNZ2UyN3FseVFzSXVSakpRWHloR3o4bk5LVE1zWkw4cF9KT3E4OHJCRXFlWTZUbzhkb0VnT2J0T0RDeUNnXzZSV0lBZ1BGXzUzVWNpb25YZUR3TUZCQkhCR1l0T25wV2lEYkN5dkRWOGt4WU5yQmtR?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYUdKeDVjTlhrTUlxSjV4TmtFWU15NzZBUFJFT3pCVWZqSkdpLW8tdzBTSUkyQTRQXzViZjdraWhRVnZIRkVOT05Bckl4ZjhFMUtsRkN5NEZicnd5TXhVcTNwSUlPY1huRWRRM0VxVHJRVEZDNF9sVTZwXzhZSnQ4S3pveGp0RnJjbmF2YkhhdnFOMmdSNm02ejlvbWNEMkUxYWo2amdrdjRWNFlwRlBleTk0VEJJVFND?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals And 2 Other Promising Penny Stocks To Watch", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxOZEtPa3BZRW9NdlBuVWxLS1pGNXF3ei1qOW43Z0psSDRXbkc1TXVSYUh1MTZDdU9FZF9JSlZCcENNMGstckJIVUYzSEVEZ3JoREhaUUtOaWNsTHNvb3VZYUNvUC1Xd0NRek9VdWdXaVJEaDNWLTRVZ201eGkxRkVmWkFhaEdnc3ZsQk8teGFLeGZETzlGZTFoT1BnRklzLUNKUTlTd0lwTXN1Q3R6U0ozblBLc1lFTDdRM2lmaHViQk9uOXRlTmFkcW55RlJWVFJ0M1ZadWdkeEpXVFluWDg5d1p6bjg2V0dqdF82SEFweHJMM3g0aWotTEdWYU8?oc=5", "source_name": "PR Newswire", "published_at": "2025-02-11T08:00:00+00:00", "published_display": "11 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc. (ORMP) Stock Price, Chart, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE5MRFJTbGxpMF8xT0xxZ2MwYWRkSzdmclpEWHg1bUVIMGtBbHpxMjMtN1FXMzNCcWhoRFd4eDdrRlRPZGx6OU0xbDkyTlBULWM?oc=5", "source_name": "Securities.io", "published_at": "2024-10-10T00:58:31+00:00", "published_display": "10 Oct 2024 00:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5wYTNPM2tOa2JqT1Y0U0R3VDExaTFMZnR2U096NGlyd1JjQ1dZQ0VBQmt2ZmRPZndoY0twRmZxZDhwWjNkY19pMFN5N2ZKaFgwYVpxa1gxZ3U3Zw?oc=5", "source_name": "MarketBeat", "published_at": "2015-06-12T10:21:26+00:00", "published_display": "12 Jun 2015 10:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback", "summary": "Oramed Pharmaceuticals (ORMP) stock is reflecting a strategic pivot following the discontinuation of its oral insulin program for type 2 diabetes due to insufficient efficacy. The company, a small-cap clinical-stage biotech, is now focusing its oral drug delivery technology on ot", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/oramed-stock-trades-quietly-as-diabetes-pill-strategy-pivots-after-fda/69789385", "source_name": "Ad Hoc News", "published_at": "2026-07-17T17:40:58", "published_display": "17 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Oramed Pharmaceuticals Inc. \u2013 NASDAQ:ORMP", "summary": "This article provides financial information for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), specifically focusing on its forward price-to-sales ratio. It appears to be a financial data snippet from a platform like TradingView, listing company details and market data. The content ", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T13:43:24", "published_display": "09 Jul 2026 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Oramed Pharmaceuticals Inc. \u2013 NASDAQ:ORMP", "summary": "This article provides general financial information for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), focusing specifically on its enterprise value to EBIT forward. It indicates that such financial data is available through TradingView, which sources its information from ICE Data S", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T00:12:02", "published_display": "09 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospects", "summary": "Oramed Pharmaceuticals is drawing investor attention due to its oral drug delivery platform, which aims to develop capsule-based alternatives to injectable biologic drugs. The Nasdaq-listed biotech focuses on clinical-stage development, with a notable project being an oral insuli", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/oramed-pharmaceuticals-highlights-oral-drug-platform-as-investors-assess/69726099", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T18:34:19", "published_display": "08 Jul 2026 18:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lifeward Enters Securities Purchase Agreement Under Oramed Financing Framework", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/lifeward-enters-securities-purchase-agreement-212258744.html", "source_name": "MT Newswires", "published_at": "2026-07-07T21:22:58+00:00", "published_display": "07 Jul 2026 21:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals outlines its oral drug strategy as Nasdaq-listed biotech pursues long-term gr", "summary": "Oramed Pharmaceuticals, a Nasdaq-listed biotechnology company, is focused on developing oral formulations of injectable drugs for metabolic and liver diseases. The company aims to improve patient convenience and adherence by leveraging proprietary oral delivery platforms that pro", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/oramed-pharmaceuticals-outlines-its-oral-drug-strategy-as-nasdaq-listed/69715057", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:41:34", "published_display": "07 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Oramed Pharmaceuticals Inc. \u2013 NASDAQ:ORMP", "summary": "This article focuses on the \"Price to earnings forward\" metric for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), as presented on TradingView. It provides a brief financial overview for the company, indicating key data points and the source of the market and reference data.", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T04:10:23", "published_display": "06 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Oramed Pharmaceuticals Inc. \u2013 NASDAQ:ORMP", "summary": "This article focuses on the \"Price to book forward\" metric for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP). It provides a high-level overview of the company's financial data available on TradingView, listing the market and stock information. The content primarily acts as a placeho", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T18:09:21", "published_display": "04 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Oramed Pharmaceuticals Inc. \u2013 NASDAQ:ORMP", "summary": "The article provides a financial metric, \"Enterprise value to revenue forward,\" for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP). It appears to be a stub or a section of a larger financial data page, showing the company's ticker, exchange, and market status. The content itself does", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T10:40:36", "published_display": "04 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Avraham Gabay Sells 73,360 Shares of Oramed Pharma", "summary": "Avraham Gabay, CFO of Oramed Pharmaceuticals Inc's subsidiary, sold 73,360 shares of ORMP on July 1, 2026, reducing his holdings to 671,785 shares. This sale aligns with a trend where Gabay has sold shares but made no purchases over the past year, while the company has seen two i", "url": "https://www.gurufocus.com/news/8943750/insider-sell-avraham-gabay-sells-73360-shares-of-oramed-pharmaceuticals-inc-ormp", "source_name": "GuruFocus", "published_at": "2026-07-03T00:41:05", "published_display": "03 Jul 2026 00:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals COO & Cbo Sold Shares Worth Over $611K", "summary": "Oramed Pharmaceuticals' COO & CBO, Hexter Joshua, sold 137,000 shares of common stock worth $611,431 on July 1, 2026. The transaction was conducted under a Rule 10b5-1 plan adopted on March 30, 2026, with shares sold at a weighted average price of $4.463. Following this sale, Hex", "url": "https://www.tradingview.com/news/tradingview:23ca4ee733ca8:0-oramed-pharmaceuticals-coo-cbo-sold-shares-worth-over-611k/", "source_name": "TradingView", "published_at": "2026-07-02T20:41:06", "published_display": "02 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (NASDAQ: ORMP) COO sells 137K shares after option exercise", "summary": "Oramed Pharmaceuticals' COO and CBO, Joshua Hexter, exercised 50,000 stock options at $3.69 per share and subsequently sold 137,000 common shares at a weighted average price of $4.463 per share. These transactions, which occurred on July 1st and 2nd, 2026, were conducted under a ", "url": "https://www.stocktitan.net/sec-filings/ORMP/form-4-oramed-pharmaceuticals-inc-insider-trading-activity-08cbc29dc66d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:41:06", "published_display": "02 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORAMED (NASDAQ: ORMP) CFO executes pre-planned sale of 73,360 shares", "summary": "Oramed Pharmaceuticals Inc.'s Chief Financial Officer, Avraham Gabay, sold 73,360 shares of common stock on July 1, 2026, at a weighted average price of $4.5085 per share. This transaction was part of a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. Following th", "url": "https://www.stocktitan.net/sec-filings/ORMP/form-4-oramed-pharmaceuticals-inc-insider-trading-activity-32c6febd7051.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:41:05", "published_display": "02 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Incorporated Financial Disclosures & SEC Filings", "summary": "This article provides access to Oramed Pharmaceuticals Inc.'s SEC filings and other financial documents. It lists earnings reports, quarterly (10-Q), and annual (10-K) reports from Q1 FY2021 through Q1 FY2026, highlighting key financial outcomes like net income and strategic deve", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/documents/", "source_name": "TradingView", "published_at": "2026-07-02T07:41:06", "published_display": "02 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ORAMED PHARMACEUTICALS INC. For: 1 July By Investing.com", "summary": "This article from Investing.com reports on Form 144 filings for ORAMED PHARMACEUTICALS INC. for July 1st. It emphasizes that trading in financial instruments and cryptocurrencies carries significant risks and advises investors to be fully informed before making investment decisio", "url": "https://m.za.investing.com/news/stock-market-news/form-144-oramed-pharmaceuticals-inc-for-1-july-93CH-4352375?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T16:39:17", "published_display": "01 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (NASDAQ: ORMP) Form 144 notes 93,360 RSU shares on 06/18/2026", "summary": "Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) filed a Form 144 revealing 93,360 shares of Common Stock linked to the vesting of Restricted Stock Units (RSUs) on June 18, 2026. The filing indicates the shares were issued without consideration, with Nasdaq listed as the market and an ", "url": "https://www.stocktitan.net/sec-filings/ORMP/144-oramed-pharmaceuticals-inc-sec-filing-d91af988e116.html", "source_name": "Stock Titan", "published_at": "2026-07-01T15:48:05", "published_display": "01 Jul 2026 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "137,000 shares flagged for sale by Oramed (NASDAQ: ORMP) in Form 144", "summary": "Oramed Pharmaceuticals has filed a Form 144, indicating proposed sales of 137,000 common shares with an associated value of $658,970.00. The filing also notes 108,000 shares issued from RSU vesting in 2023 and 50,000 shares acquired from employee stock option exercises on July 1,", "url": "https://www.stocktitan.net/sec-filings/ORMP/144-oramed-pharmaceuticals-inc-sec-filing-3d5184b6b74a.html", "source_name": "Stock Titan", "published_at": "2026-07-01T15:39:17", "published_display": "01 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (NASDAQ: ORMP) revises bylaws and restructures Scilex note obligations", "summary": "Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) has updated its corporate bylaws, refining procedures for stockholder action by written consent. Concurrently, Oramed has renegotiated and extended the payment schedule for approximately $36.2 million in debt owed by Scilex Holding Compa", "url": "https://www.stocktitan.net/sec-filings/ORMP/8-k-oramed-pharmaceuticals-inc-reports-material-event-8d02b5b7c2d2.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:09:35", "published_display": "30 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BML Investment Holds 2.5% of Oramed (ORMP) in Amended 13G/A", "summary": "BML Investment Partners, L.P. has filed an amended Schedule 13G/A, reporting a beneficial ownership of 1,026,269 shares, or 2.5% of Oramed Pharmaceuticals Inc. (ORMP). Braden M. Leonard is identified as the indirect owner through BML Capital Management, LLC. The filing specifies ", "url": "https://www.stocktitan.net/sec-filings/ORMP/schedule-13g-a-oramed-pharmaceuticals-inc-amended-passive-investment--bf75d0084773.html", "source_name": "Stock Titan", "published_at": "2026-06-29T14:34:39", "published_display": "29 Jun 2026 14:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOTmF4N3I4SlM0NGdnaUk4N1ZIYW9TRUNrYlNFYzNzSTlsd2hoVkhwc0ZuQWNCV3Vzdjl6Q2FxdzBaVFlQa1R2SklKWEo2UWRlZ1lfZjR3TnZEdDlmM3otWTNVLXByTFl5RDVfNzdvWnRrSFdZSElBbjBVZWpuUVFpMzN1LXVNbGJBdnJqNUQ0TXk2MDcyT0xpa0ljWjFUblV1UHhONl83UEk2RmV4bWwwS0JzOHVDQzNZbGkwTkI1Mzl5Wk5zYTdpeXdlR2k?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Incorporated Actuals & Estimates (MUN:OJU1)", "summary": "This article provides financial actuals and estimates for Oramed Pharmaceuticals Incorporated (MUN:OJU1), including income statement, balance sheet, and cash flow data. It also covers analyst price forecasts, historical stock performance, upcoming earnings dates, and key financia", "url": "https://www.tradingview.com/symbols/MUN-OJU1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:20", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Incorporated Actuals & Estimates (DUS:OJU1)", "summary": "This article provides financial actuals and analyst estimates for Oramed Pharmaceuticals Incorporated (DUS:OJU1), including income statement, balance sheet, cash flow, and valuation metrics. It offers a stock forecast with max and min estimates, historical price data, and details", "url": "https://www.tradingview.com/symbols/DUS-OJU1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:54", "published_display": "26 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet \u2013 Company Announcement - FT.com", "summary": "Oramed Pharmaceuticals Inc. issued a letter to shareholders detailing significant developments, including its inclusion in the Russell 2000 and 3000 indexes, substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in cash and asset", "url": "https://markets.ft.com/data/announce/detail?dockey=600-202606251135PR_NEWS_USPRX____LN92360-1", "source_name": "Financial Times", "published_at": "2026-06-25T16:35:00", "published_display": "25 Jun 2026 16:35", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:ORMP)", "summary": "This article provides an overview of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), detailing its stock performance, financial actuals and estimates, and analyst forecasts. As of the article's publication time, ORMP's stock price was $5.00, having increased significantly over the pa", "url": "https://www.tradingview.com/symbols/NASDAQ-ORMP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T15:40:10", "published_display": "25 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed\u2019s portfolio swells: Alpha Tau stake up $128M, Scilex loan repaid", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQbXJSSnI4UXYzVXYwNW44SFlScTBHVXZ0RC04UjBJVmd4MlJGUk9hYVQybUlOakR6bmlWbl9CbENVTVRJVTViZnRvanhzWHVZTDd6TEtVTHZteDJTa29HQmw5SjBYcmtrcE9qVmUyS24xRFlSa202WEVpekNRaGlzVnZQU3NHdG9SZXVtNU81WGlELTdsWlY5aVVDb0hJMVVWRHR4LTVaU2xuXzg0RGJVZ0c2a1dmUG85eW5Z?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORMP SEC Filings - Oramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Oramed Pharmaceuticals Inc. (ORMP) SEC filings, including 10-K, 10-Q, and 8-K reports. It details recent material events and financial information, such as an $18 million payment from Scilex Holdings Inc. and a declared cash dividen", "url": "https://www.stocktitan.net/sec-filings/ORMP/page-3.html", "source_name": "Stock Titan", "published_at": "2026-06-21T17:41:08", "published_display": "21 Jun 2026 17:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals to Join Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is scheduled to join the U.S. small cap Russell 2000\u00ae and broad-market Russell 3000\u00ae Indexes. This inclusion will become effective after the close of US markets on Friday, June 26, 2026, and for trading at the market open on Monday, June", "url": "https://www.morningstar.com/news/pr-newswire/20260617io85985/oramed-pharmaceuticals-to-join-russell-2000-and-russell-3000-indexes", "source_name": "Morningstar", "published_at": "2026-06-19T01:40:10", "published_display": "19 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Oramed Pharmaceuticals Inc (ORMP), noting its current valuation score of 8.94 and its ranking within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 1.45, contrasting it with recent high", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ormp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:55", "published_display": "18 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Oramed Pharmaceuticals Inc (ORMP), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis suggests a \"Sell\" signal based on moving averages and indicator", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ormp/technical", "source_name": "TradingKey", "published_at": "2026-06-18T07:38:57", "published_display": "18 Jun 2026 07:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Oramed Pharmaceuticals Inc (ORMP) currently lacks an earnings forecast score, with the Biotechnology & Medical Research industry average being 8.13. Analyst forecasts set the price target at $3.25, with no deviation between high and low estimates. The company has not yet disclose", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ormp/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:38:57", "published_display": "18 Jun 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Oramed Pharmaceuticals Inc (ORMP), identifying major individual and institutional holders. It provides a breakdown of shareholder types and tracks institutional shareholding changes over several quarters, along with significant sh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ormp/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T14:10:19", "published_display": "17 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (ORMP) Set to Join Russell 2000 and 3000 Indexes in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQalBhNEh1TDlGS05ndkNLMEdqMXlKcHN1NENRNWhZTDlnZ2NaQzFQMXR2dVAzeEg3UUhock03aS0zRmE2RndjdXgybURQVDBMS1NBZTdTZ0NuQURfZHdRaDlUZzVvLWhQZ2Q3UDhwa3dzRzdhWl9nWi1BV0o3elFVZm8wVzhHZnMxVVk0c0lRSG5HaHF2UThKQk1Kb0xaTHl3VFFtSlFlYlZvTE9NM3VkeE9SQzNxcmFucXhhWk1XWk1HbEhmRk54R25wOS1vX2Qxd0M2WnkwYw?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals (ORMP) Faces Selling Pressure; Key Levels in Focus - Risk Reward Setups", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOdXAtVVZWOVZxLXNkYlk1RllZZzBjZWZRQUtLU1lCRy1LS181ei1JOGZHVVdIM09Nc0F0ZkN5OGlWZ0JVQjd3MlV4VWtvYjQ0TEpqb0FrZEp2SnRhV21udks3Y19XbkF5SlU0dmtkZGdPX0FySDZoLWJhZ2taclQ4SlhLR0xPZWtmR2Q3SHl6TElNQ1N1Ui1BVHpxcnNhZW83LTlmQ1BDVWd1TFRKM3Q3aUJRbnY?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals (ORMP) Holds Near Key Support Amid Modest Decline - Percent Below MA", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPZ0xPclBBQjV3TV8tT0pCZlFWakFMQWhrX2ZLeWVJYzVIWTd4Z2haU2h6d0d3M3dKRjZfZXR5M1NfYmxiRDNQaldXZEpvczc1RVZjT0tMdm9mSjQ3cndlYXVMVHY5Q1dhODAyZGt4TnkwZUlxaTZvUFFXanE0MGdUdk15SGJvbEJfVGZzc2p5cHQyOWJrUFpPMmhRVm9saTA4UGZUcE95MjFxUnYzRUZoZV9lcl9WUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxONmpPQmZvbGJpM1R4MTR6WHhUVVV0eHFLZjhkaW5oamlpWS1kZWZ1OFVjcTdiaW5iS0EtbTdhMHg2OU9jSlE1UUNOZXVuWFpmSWlRNW1kUEhFdlA0c1FZMDZXNy1Ec1J3bDFoLURQV3lUOHNjVng0RjNQZ3RsOURnRlprRGd4bTRhdXlZSHJDUDl4UzJhZzlXbnA0eXBmWGhiYkxabUFFUlVJaG50M2RmeGhMXzJRbG15NDNPYS1rUm5GQ0c2T0l6VllvOEdLMWc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oramed-q1-earnings-snapshot-213617884.html", "source_name": "Associated Press", "published_at": "2026-05-19T21:36:17+00:00", "published_display": "19 May 2026 21:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks", "summary": "", "url": "https://finance.yahoo.com/news/spotlight-oramed-pharmaceuticals-two-other-120523659.html", "source_name": "Simply Wall St.", "published_at": "2026-05-13T12:05:23+00:00", "published_display": "13 May 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNYWVuQ19uenhfR01hUzJmcUp1YjVkektPcDBPNEV6UzlLdXZ3WDlleWFCQWtLYUE0T1ZOQjhMSWc4bGRjTlF1Xzh1NFlQWDlWSVBCNG9sVy1OUVdPQVZBZUU3eXJneXhsY0xjY2hQRUVLZ2EtZ1ptXzZTTC0yZWtZZWJmSlNZQm9zWHVKdDNsTmtZN3RzR0JMTURnMW5rbV9LZ1RIZ251RkppV2c?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top 10 healthcare stocks with highest dividend yield amid volatile markets (ORMP:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQaU40M2dnNk1rd3Nna1dqVGhmX0ZscDJHUkR2TjF6dWxZaGZoV3FYMWVCdXU0T3NHVlJFanlic2t3VG5wRDBBZ2lnSXpBWWJXSmRYMTlJcFlqcU1WVFptbHR5VEh3cDRJT095UURnUGptdmZTOV92MDQydEN5ZUVxYndIMEdRakdqOVRPOXV4WjhwOGlnSlVPdjVpV0ZVQTRSakpyMEdPcTFIbm5iaXROdTln?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed and Lifeward Announce Strategic Transaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOczBySEF1Vy1BNUR4d2x2ejFfa1YtMnd3djB4bEJ1V2IwWkczZy01a19ybkpUT1FkYndqa3JQTTNLcURXc0lYUXl0aHNGYnQzR1l1WVM5dzFiSXBSTmxEbDZSTi1MU3kzX2pwRmdMdm1BaEduSEpvZ3RkRUthLWhhaGxndnJkd2lJU1lGeERIX2dvYlp3bW94Y1c3UUlhLXExYlV1Q3NUZnVGQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxPc3NEdVhOTFlFQ0NyS2E4aHR3UGNiVjBCMjZpZTNUSm5VQnNWSDgyTlFDZTRoNzh5aWdlZkdGczc3TzZhbE5tQlpYWGpablZvZHpYVUg1WVBueFpsMGs5Ql81T01ScFBYWVF0ZUpoNHRYR0hvVERSMFNBejcwQ1ZUcVlSWG5RZ0JFRUY2aGpENTFlOUEwb1VPVHU3NXI3Z2hFLVBNZ2UyN3FseVFzSXVSakpRWHloR3o4bk5LVE1zWkw4cF9KT3E4OHJCRXFlWTZUbzhkb0VnT2J0T0RDeUNnXzZSV0lBZ1BGXzUzVWNpb25YZUR3TUZCQkhCR1l0T25wV2lEYkN5dkRWOGt4WU5yQmtR?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYUdKeDVjTlhrTUlxSjV4TmtFWU15NzZBUFJFT3pCVWZqSkdpLW8tdzBTSUkyQTRQXzViZjdraWhRVnZIRkVOT05Bckl4ZjhFMUtsRkN5NEZicnd5TXhVcTNwSUlPY1huRWRRM0VxVHJRVEZDNF9sVTZwXzhZSnQ4S3pveGp0RnJjbmF2YkhhdnFOMmdSNm02ejlvbWNEMkUxYWo2amdrdjRWNFlwRlBleTk0VEJJVFND?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals And 2 Other Promising Penny Stocks To Watch", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxPU0pmdm5tZXlyN1hHRWRDelc3SDBvWWRnSnZiZzNLeHdBNExiUElpdm1PV1E2UldnX2h6a0EwR2NFY0JpYjBaS0hFejJNQThCNHlsQTFfa05acmZOSlJXNWpKbktDbHJudThkNnM4U1lzaHozUGZpc2h4bnJYZ29Va0ZWeXZmcWtRV2d3YllSaGhTVzFoekhTWnJQenpOeDdqXzZZWFdVc3UzaVlTVTMwMjRPb3E0RWpoN1JvQmZNYVU4N0hTbzlGdnVPanBtamlUS3NnQmFzMzRESHNPTkpneFF5My1SXzQxNnFjddIB8gFBVV95cUxQRXdqRnRNSE9zdURxQjJfREhZdGowZTJab05JVkpFZ3BXdWN5VTEzc2pKYlJuaXhwWnRjVHYtRXdjdFlxYU45QnFlYTM1YUhjRGVmNFo0MUE1dzJCR0c4b0ZKamFwNEJUNWJTOEVNck9jMDYzTUpBMmVtZlUyV0trWThac1AzME13SFNwaHRDM3pXZW9rU3l4bmJJVXM0SWU0cjUxb0ZkZzdqS2hfVXM1cnBvbW5XT09pcUdNcU8wdzJxcEhWdnJxTktUWEs0UlNpSkFDUV9odjZMTDJDVW5EMmhaRXRYTmVLYWxOcFN1THhqUQ?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxOZEtPa3BZRW9NdlBuVWxLS1pGNXF3ei1qOW43Z0psSDRXbkc1TXVSYUh1MTZDdU9FZF9JSlZCcENNMGstckJIVUYzSEVEZ3JoREhaUUtOaWNsTHNvb3VZYUNvUC1Xd0NRek9VdWdXaVJEaDNWLTRVZ201eGkxRkVmWkFhaEdnc3ZsQk8teGFLeGZETzlGZTFoT1BnRklzLUNKUTlTd0lwTXN1Q3R6U0ozblBLc1lFTDdRM2lmaHViQk9uOXRlTmFkcW55RlJWVFJ0M1ZadWdkeEpXVFluWDg5d1p6bjg2V0dqdF82SEFweHJMM3g0aWotTEdWYU8?oc=5", "source_name": "PR Newswire", "published_at": "2025-02-11T08:00:00+00:00", "published_display": "11 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc. (ORMP) Stock Price, Chart, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE5MRFJTbGxpMF8xT0xxZ2MwYWRkSzdmclpEWHg1bUVIMGtBbHpxMjMtN1FXMzNCcWhoRFd4eDdrRlRPZGx6OU0xbDkyTlBULWM?oc=5", "source_name": "Securities.io", "published_at": "2024-10-10T00:58:31+00:00", "published_display": "10 Oct 2024 00:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5wYTNPM2tOa2JqT1Y0U0R3VDExaTFMZnR2U096NGlyd1JjQ1dZQ0VBQmt2ZmRPZndoY0twRmZxZDhwWjNkY19pMFN5N2ZKaFgwYVpxa1gxZ3U3Zw?oc=5", "source_name": "MarketBeat", "published_at": "2015-06-12T10:21:26+00:00", "published_display": "12 Jun 2015 10:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 57, "sentiment_summary": {"positive": 9, "negative": 8, "neutral": 40, "score": 51, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.65, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 7.91, "count": 16}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.55, "count": 4}, {"event": "capital_return", "label": "Capital return", "weight": 1.45, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 4.03, "latest_week": "2026-07-17", "one_week_move": -0.2, "four_week_move": 3.9, "twelve_week_move": 4.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.344612, "market_dynamics_buy_signal": false, "relative_strength": 19.701715, "fair_value_gap": 58.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.7032, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.2% over one week, +3.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 49, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "Seeking Alpha", "count": 3}, {"label": "PR Newswire", "count": 3}, {"label": "AD HOC NEWS", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 16}, {"label": "Balance sheet", "count": 4}, {"label": "Capital return", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.2% over one week, +3.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback"}], "updated_at": "2026-07-22T23:47:59.805666+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}